• Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies

  • Jul 24 2024
  • Duración: 38 m
  • Podcast

Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies Por arte de portada

Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • touchIN CONVERSATION for touchRESPIRATORY

    Listen to a medical oncologist and a pathologist as they discuss HER2 alterations in non-small cell lung cancer (NSCLC), including the different types of HER2 alterations, key considerations for HER2 testing and the latest data for HER2-targeting treatments.

    The experts

    • Prof. Enriqueta Felip - Medical Oncologist, Vall d'Hebron University Hospital, Barcelona, Spain
    • Prof. Keith Kerr - Aberdeen University Medical School and Aberdeen Royal Infirmary, Aberdeen, UK

    This touchPODCAST is for HCPs outside of the UK only.

    This activity is funded by an independent medical education grant from AstraZeneca, and is jointly provided by USF Health and touchIME. touchIME is an EBAC® accredited provider.

    For further information visit our website:

    https://touchrespiratoryime.org/her2_nsclc_testing_and_targeted_therapies/
    Más Menos
activate_primeday_promo_in_buybox_DT
Ciencia
Más Menos

Lo que los oyentes dicen sobre Decoding HER2 in NSCLC: Advances in biomarker testing and targeted therapies

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles